marijuana stocks news Black Friday / Cyber Week Sale and MMPR Update

TORONTO, ON–(Marketwired – Nov 26, 2014) –  Easton Pharmaceuticals (OTC: EAPH) has in the past month taken steps to enter into the fast growing Vaporizer market. On Black Friday and Cyber Monday we will be offering a 25% to 40% discount on select products. 25% discounts will apply for premium branded items while 40% will apply to non premium products. We believe there is adequate current inventory to satisfy anticipated demand, but selling out is always a possibility.

If any current shareholder wishes to purchase products we will extend a 10% additional coupon code: “Easton Tough.” Have a Happy Thanksgiving and be safe by shopping from home at

In addition to our Vaporizer venture we are committed to opening an initial flagship retail location and currently looking for suitable retail locations in the Metropolitan Greater Toronto area which is currently the 4th largest city in North America. Retail locations self advertise themselves and are currently a proven revenue generating model here in Toronto and the North East in general.

In the Canadian Medical Marijuana industry it would seem that positive developments have materialized whereby Health Canada has issued an MMPR license to Broken Coast Cannabis of British Columbia.

If Health Canada has restarted issuing licenses for the fall/winter season Easton’s Medical Marijuana joint venture initiative could be next on that list for inspection and licensing given it is one of the first to have applied and then received a letter to build from Health Canada under the new MMPR system.

In additional Medical Marijuana related news, Easton continues discussions on two major medical marijuana markets, California and Colorado. More details on these discussions will be available by the second week of December. To provide more transparency to our shareholders, Easton has formulated partial disclosure agreements that will allow investors to have information as to the physical location and size of the grow pursuant to the completion of Due Diligence period.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company owns, designs, develops, and markets topically-delivered drugs and therapeutic / cosmetic healthcare products, focused on cancer and other health issues geared towards male and female sexual dysfunction, wound healing, pain, motion sickness, scar and stretch marks, cellulite, varicose veins and other conditions. The company has ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 50% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when used in the preceding of discussion, the words “hope,” “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.


Carla Pepe
Easton Pharmaceuticals Inc.
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$ERBB Roll-Out Attracts Valued and Capable Partners

The American Green Machine Roll-Out Attracts Valued and Capable Partners American Green,…

Cronos Group Inc. (CRON) CEO, Mike Gorenstein, to Speak at the 23rd Annual CIBC Western Institutional Investor Conference

Cronos Group Inc. CEO, Mike Gorenstein, to Speak at the 23rd Annual…


SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against…